Editas Medicine Inc (EDIT)vsInsmed Inc (INSM)
EDIT
Editas Medicine Inc
$2.25
-6.25%
HEALTHCARE · Cap: $229.02M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1397% more annual revenue ($606.42M vs $40.52M). EDIT leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
EDIT
Avoid20
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
Trading at 8.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EDIT
EDIT has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : EDIT
The primary concerns for EDIT are Price/Book, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
EDIT profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
EDIT carries more volatility with a beta of 2.19 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
EDIT generates stronger free cash flow (-36M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 20/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Editas Medicine Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?